AstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to a generic rival from India’s Glenmark, although it is unclear when the
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
